Nordic Life Science 1
TOP STORIES BUSINESS Stefan K. Nilsson, CEO, Lipi
gon YEPTI IS THE FIRST FDA-APPROVED intravenous (IV) treatment for migraine prevention. Color amet this “With the approval of Vyepti, I am pleased that we are now able to offer a new IV therapy that achieves the key treatment goal of preventing migraine over time while also delivering on the need for earlier onset of efficacy,” says Deborah Dunsire, CEO, Lundbeck. The efficacy and safety of BUSINE S S D E A L Vyepti was demonstrated in two phase III clinical trials. The clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of Vyepti as early as day 1 postinfusion, and the percentage of patients experiencing a migraine was lower for VYEPTI than with placebo for most of the first 7 days. The safety of VYEPTI was evaluated in 2 076 patients with migraine who received at least one dose of Vyepti. Deborah Dunsire, CEO, Lundbeck HE DRUG CANDIDATES WERE jointly generated with Secarna Pharmaceuticals under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a transaction. “Secarna’s LNAplus platform has given us fully optimized clinical candidates that we are looking forward to bringing into IND-enabling studies,” says Stefan K. Nilsson, CEO, Lipigon. 10 NORDICLIFESCIENCE.ORG “The acquisition is in line with Lipigon’s business model to fully control our pipeline until out-licensing or market introduction. We believe that this agreement will make our case more attractive for investors.” Inhibiting the ANGPTL gene family members ANGPTL3 and ANGPTL4 will positively affect plasma lipid levels, states the company. Drugs targeting these gene products could be used for treating orphan indications such as Familial Chylomicronemia Syndrome or Homozygote Familial Hypercholesterolemia, but also more common diseases such as cardiovascular, metabolic liver and kidney diseases. PHOTO OLA JACOBSEN